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Summary
Background: Maspin, a recently identified protein related to
the family of serpins, is believed to play a role in human
breast cancer. In an effort to improve the present methods of
detection, we have developed a reverse-transcriptase poly-
merase chain reaction (RT-PCR) assay for maspin transcript
to identify small numbers of mammary carcinoma cells in the
peripheral blood and bone marrow of patients with breast
cancer.
Patients and methods: Five non-neoplastic mammary
tissue samples, 13 breast cancer specimens as well as 17
peripheral blood and 4 bone marrow samples from normal
subjects were screened for the presence of maspin mRNA by
RT-PCR. The same assay was applied to peripheral blood or
bone marrow samples obtained from 29 patients with stages I
to IV breast cancer.
Results: By RT-PCR it was possible to amplify maspin
mRNA in all of the primary and metastatic breast cancer
specimens, but in none of the normal hemopoietic samples
from healthy donors. Thus, detection of maspin transcript in
the peripheral blood or marrow of a patient known to have
breast cancer is indicative of the presence of mammary car-
cinoma cells. In reconstitution experiments, maspin RT-PCR
reliably detected 10 mammary carcinoma cells in 1 million
normal peripheral-blood mononuclear cells (PBMCs). None
of the 9 patients with stages I, n, or HI breast cancer had
maspin transcript in peripheral blood. Of note, 3 of 9 pa-
tients with stage IV breast cancer receiving systemic therapy
at the time of sample collection, but only 1 of 11 patients
with stage IV not receiving therapy, had detectable maspin
transcript in peripheral blood. Moreover, 3 marrow speci-
mens from stage IV patients tested positive by this assay.
Conclusions: This pilot study suggests that maspin RT-
PCR assay is a sensitive, specific and sufficiently rapid meth-
od for detection of small numbers of circulating cells and
marrow micrometastases in breast cancer patients. The pos-
sibility of applying this assay in the detection of tumor cell
contamination of both marrow and stem-cell apheresis har-
vests of breast cancer patients merits further investigation.
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Introduction
Sensitive detection of occult carcinoma in peripheral
blood and bone marrow of patients with breast cancer
may have important prognostic and therapeutic impli-
cations [1, 2]. Immunohistochemical staining [3] and
flow cytometry [4] with one or a panel of monoclonal
antibodies against cell surface glycoproteins or cyto-
keratins are often highly sensitive but may be subject to
false-positive results when antibodies cross-react with
normal peripheral blood cells [1], as well as to false-
negative results when an inadequate number of cells is
evaluated [5]. Thus, in the detection of a very low num-
ber of tumor cells, immunohistochemical analysis
should be combined with clonogenic assays [5], which,
however, are laborious and require several weeks of tis-
sue culture. To circumvent the problems inherent in
immunohistochemical and cell culture techniques,
polymerase chain reaction (PCR)-based assays were
recently introduced [6]. The effectiveness of PCR in the
detection of human tumor cells depends upon a quali-
tative difference in gene structure (DNA) or expression
(RNA) between the malignant and the normal back-
ground cells. Studies of PCR amplification of tumor-
specific DNA sequences are possible mainly in hema-
tological malignancies which often show consistent and
well-characterized molecular abnormalities, but are of
limited importance in solid tumors where such abnor-
malities are uncommon [6]. Thus, the best approach for
the molecular detection of circulating solid tumor cells
is based on the reverse transcription and amplification
of tissue-specific RNA transcripts which are not ex-
pressed in normal hemopoietic tissues and may be used
as markers of tumor cells in the blood, thereby avoiding
the requirement for a DNA sequence abnormality.
Reverse-transcriptase polymerase chain reaction (RT-
PCR)-based assays for prostate-specific antigen in
prostate cancer [7, 8], for carcinoembryonic antigen in
colorectal cancer [9], for tyrosinase in melanoma [10]
and for tyrosine hydroxylase mRNA in neuroblastoma
[11] are some of the most successful applications of this
approach, allowing the sensitive detection of circulating
tumor cells in patients with solid cancers. At present,
however, the application of PCR in breast cancer tumor
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detection is limited because of the lack of relevant
molecular markers. In fact, the value of RT-PCR-based
assays for cytokeratin 19 (CK19) [12] as well as for the
MUC1 [13] gene as markers of mammary carcinoma
cells was recently questioned on the basis of the docu-
mented expression of both of these genes in either the
peripheral blood mononuclear cells (PBMCs) [14] or
the lymph nodes [15] of subjects without cancer.
Thus, in order to improve existing molecular meth-
ods of detection of small numbers of circulating cells in
breast cancer patients, we have evaluated the RNA
transcript encoding for maspin as a specific marker for
mammary carcinoma cells. Maspin is a recently iden-
tified protein apparently related to the serpin family of
protease inhibitors [16]. The function of maspin is still
uncharacterized, but initial studies on its expression in
human mammary tissues suggest a possible biological
role of alteration in maspin expression during the
development and progression of breast cancer [16]. In
this report, we describe the development of a new, sen-
sitive and specific RT-PCR-based assay, first docu-
menting the presence of maspin mRNA in all primary
and metastatic breast cancer specimens examined and
its absence in a series of normal hemopoietic tissues,
thereby providing evidence that the detection of
maspin transcript in the peripheral blood and/or mar-
row of a patient with known breast cancer invariably
indicates the presence of mammary carcinoma cells.
We finally describe the application of this method in
investigating the presence of circulating malignant cells
in the peripheral blood specimens of a well-charac-
terized series of breast cancer patients at different
stages of the disease.
Patients and methods
Patient samples and RNA preparation
The study population consisted of 29 patients with histologic diag-
noses of breast cancer at different stages: 4 had stage I, 3 had stage
II, 2 stage IU, and 20 stage IV, and 9 were receiving systemic therapy
at the time of sample collection. After procuring their informed con-
sent, 5-10-ml samples of heparinized venous blood or bone marrow
aspirate were taken from patients at various time points during treat-
ment and processed as described below. Seventeen peripheral blood
and 4 bone marrow samples were also collected from healthy
donors. Peripheral blood mononuclear cells (PBMCs) were pre-
pared by centrifugation on Ficoll-Hypaque density gradient (Ficoll-
Hypaque; Pharmacia, Uppsala, Sweden). Thirteen fresh breast can-
cer specimens (10 primary tumors and 3 skin metastases) and 5
non-neoplastic mammary tissue biopsies were obtained from sur-
gical resection specimens, snap-frozen in liquid nitrogen within 10
min of their arrival in the pathology specimen reception area and
kept frozen until tissue homogenization prior to extraction. Total
RNA was extracted according to the acid guanidium thiocyanate-
phenol-chloroform standard method [17].
cDNA synthesis and PCR
One microgram of total RNA was reverse transcribed according to
the manufacturer's instructions in 1 x RT buffer (Gibco BRL Life
Technologies, Gaithersburg, MD, USA) supplemented with 0.01 M
dithiotreitol (DTT), 200 units of cloned Moloney murine leukemia
virus reverse transcriptase (Gibco BRL), 1 mM of each dNTP
(Pharmacia) and 200 units of RNAse inhibitor (Boehringer, Mann-
heim, Germany) in a final volume of 30 \i\ incubated at 42 "C for 60
min. For amplification, primers designed from the coding sequence
of the human maspin cDNA (Gene Bank accession number
U04313) were used. The sequences of oligonucleotide primers
were as follows: 5' TCAAGCGGCTCTACGTAGAC 3' sense and
5' CCTCCACATCCTTGGGTAGT 3' antisense. PCR was carried out
in a 50 ul mixture containing 1 x PCR buffer (10 mmoI/L Tris, pH
8.3, 50 mmol/L KCI, 2.5 mmol/L MgCl2, 0.01% gelatin), 125|i.mol/l of each dNTP, 50 pM of each external primer, 1 unit of Taq
DNA polymerase (Boehringer, Mannheim) and one-sixth of the
cDNA sample. After 35 cycles of amplification (1 min at 95 "C, 1
min at 55 "C, and 1 min at 72 *C), one-fifth of the amplified product
was separated electrophoretically in a 1.5% agarose gel, stained with
ethidium bromide and observed under UV light. The length of the
primary amplified product in the positive samples was 446 base
pairs (bp). In order to assess the specificity of the amplified band,
one-fifth of the RT-PCR product was subjected to electrophoresis
on a 1.5% agarose gel blotted on Zeta-Probe GT Membrane (Bio-
Rad Laboratories, Hercules, CA, USA) and hybridized with an
internal oligonucleotide probe (5' GCCTCCATGTTCATCATCT-
GCACTGGTTTGGTGTCTGTCT 3') end-labelled with -32 P-ATP
(Amersham-USB, Cleveland, OH, USA). To increase the sensitivity
of the RT-PCR assay 2.5 |*1 of the primary amplified product was
subjected to a second PCR under the same conditions for 35 cycles
with nested oligonucleotide primers. The expected length of the re-
amplification product was 175 bp. The sequences of the nested
oligonucleotide primers were as follows: 5' GATCTCACAGATG-
GCCACTT 3' internal sense and 5' GCACTGGTTTGGTGTCT-
GTC 3' internal antisense. Negative controls, including distilled
water and the reaction mixture without the reverse transcriptase
enzyme, were also present during the RNA extraction procedure
and equalled or exceeded the number of the assayed samples. All
standard recommended procedures were performed to avoid false-
positive results: 1) the various steps of the procedure (RNA purifi-
cation, PCR and gel electrophoresis) were physically separated; 2)
RNA extraction and PCR were performed in duplicate for each
sample and a result was considered definitive when confirmed in
different experiments. In all of the specimens tested for maspin
expression the presence of intact RNA, an adequate cDNA syn-
thesis as well as the absence of inhibitors were confirmed by a single
round of RT-PCR using ABL sequence-specific PCR primers [18].
The nested RT-PCR procedure for the detection of CK19 transcript
was previously described by Datta et al. [12]. To determine the sen-
sitivity of the maspin assay and to compare it with the sensitivity of
the CK19 RT-PCR assay, PBMCs obtained from a normal donor
were mixed with decreasing numbers of MCF7 cells. There was a
total of 1 million cells in each sample. Cells were mixed before the
RNA preparation, thereby mimicking the clinical setting for detec-
tion of mammary cells in the peripheral blood or bone marrow of
patients.
Results
Using a conventional RT-PCR-based assay a single 446
bp band was identifiable on ethidium bromide-stained
agarose gels in non-neoplastic mammary tissue sam-
ples and, more importantly, in all of the primary and
metastatic breast cancer specimens examined as well as
in the MCF7 mammary tumor cell line (Table 1; Figure
1). This fragment was confirmed by Southern blot anal-
ysis to be the fragment of the maspin gene which lies
between the two primers used for PCR (see Tatients
and methods')- The 17 peripheral blood mononuclear
cell (PBMC) and 4 bone marrow samples obtained
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Table 1. Detection of maspin mRNA in a series of mammary tissues
and haemopoietic specimens by RT-PCR.
Sample source
Breast cancer (primary tumor)
Breast cancer (metastases)
Non-neoplastic mammary tissue
Blood (healthy donors)
Normal marrow
No. cases
10
3
5
17
4
No. maspin
positive
10
3
.5
0
0
-446 bp
Maspin
Figure 1. Detection of maspin transcript in three representative
breast cancer specimens, after 35 cycles of RT-PCR assay, and
visualization of the 446 base pair (bp) amplified product on ethi-
dium bromide. Results of a representative PBMC sample from a
healthy donor were negative. NC: negative control (reaction mixture
without the reverse transcriptase enzyme). Marker VIII: molecular
weight marker (Boehringer, Mannheim).
amplification of ABL sequence, and were further
evaluated for the presence of maspin mRNA by RT-
PCR Neither the 4 patients with stage I, the 3 with
stage II, nor the 2 with stage Hi breast cancer showed
detectable maspin transcript in their peripheral blood
specimens (Table 2). Of particular interest was the fact
that 3 of 9 patients with stage IV breast cancer receiv-
ing systemic therapy at the time of sample collection
had detectable maspin transcript in peripheral blood as
detected after nested PCR and direct visualization on
ethidium bromide (Figure 3), as well as after hybridiza-
tion of the first PCR product with a specific internal
oligonucleotide probe (Table 2; Figure 4A). One of
these patients showed no detectable maspin transcript
when the peripheral blood sample was collected two
months after the end of the chemotherapy courses.
Furthermore, 1 of 11 patients with stage IV breast can-
cer not receiving therapy also had positive maspin RT-
PCR assay results (Table 2). In addition, 3 bone mar-
row biopsies from patients with stage IV breast cancer,
showing very few rumor cells at standard histologic
examination were clearly positive by this RT-PCR assay
(Figure 4B). Only one of these three patients with a
positive marrow specimen showed maspin-expressing
cells in the peripheral blood.
CK19 transcript was detected in the PBMC samples
of 8 breast cancer patients of our series and, in particu-
lar, in 1 patient with stage I, in 2 patients with stage II,
No. of MCF7cells
103 102 10 1
-446 bp
from healthy donors were negative for maspin tran-
script even after re-amplification with nested primers
and direct visualization on ethidium bromide, as well as
by hybridization of the primary PCR product with a
specific oligonucleotide probe (Table 1; Figure 1). In
contrast, 5 of these normal peripheral blood samples
tested positive for the CK19 transcript, after a nested
RT-PCR assay (data not shown). In order to assess the
sensitivity of the maspin RT-PCR assay, a mixing study
was performed using serial dilutions of the mammary
carcinoma cell line MCF7. By use of this approach, our
assay routinely detected 10 maspin-expressing mam-
mary carcinoma cells mixed with one million normal
PBMCs (Figure 2). This sensitivity was comparable to
that obtained of the CK19 RT-PCR assay, as evaluated
after an identical dilution experiment on the same
tumor cell line.
RNA samples derived from the peripheral blood of
all 29 patients with breast cancer exhibited successful
Maspin
Figure 2. Sensitivity of the maspin RT-PCR assay, evaluated after
hybridization of the first amplification product with an internal
specific oligonucleotide probe. The number of MCF7 breast car-
cinoma cells mixed with 1 million normal PBMCs is shown.
Table 2. Detection of maspin mRNA in the PBMCs of breast can-
cer patients by RT-PCR.
Breast cancer No. patients
(PBMCs)
No. maspin
positive
Stage I
Stage n
Stage III
Stage IV (no therapy)
Stage IV (therapy)
4
3
2
i l
9
0
0
Q
1
3
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-175 bp
Maspin
Figure 3. Detection of circulating breast cancer cells in representa-
tive peripheral blood samples from stage IV patients (1 PBMC and
4 PBMC), after a nested RT-PCR assay and visualization of the 175
bp amplified product on ethidium bromide. MCF7: breast carci-
noma cell line used as positive control. NC: negative control (reac-
tion mixture without the reverse transcnptase enzyme). Marker VIII
and Marker IX: molecular weight markers (Boehringer, Mannheim).
PBMCs
NC MCF7
-446 bp
Maspin
B Bone Marrows
1 2 3 NC MCF7
-446 bp
Maspin
figure 4. Detection ot breast cancer cells in representative periph-
eral blood samples (1-5) (A) and bone marrow specimens (1-3) (B)
from stage IV breast cancer patients. After 35 cycles of ampli-
fication and hybridization with a specific oligonucleotide probe, a
positive maspin signal was detectable in the PBMC samples from
patients 1 and 4 (A) and in the bone marrow sample from patient 1
(B). MCF7: breast carcinoma cell line used as positive control. NC:
negative control (reaction mixture without the reverse transcnptase
enzyme).
in 3 patients with stage IV not receiving chemotherapy,
and in 2 patients with stage IV treated with chemother-
apy at the time of sample collection (data not shown).
Discussion
We have looked at the possible use of the maspin gene
as a target for RT-PCR detection of metastasising
breast cancer cells. On the basis of initial sequence
homology studies, Zou et al. proposed that maspin is
related to the serpin family of protease inhibitors [16].
This putative function also seemed consistent with the
fact that the maspin gene was shown to be expressed in
normal mammary epithelial cells while a reduction or
even a loss of maspin expression was documented in
mammary carcinoma cell lines and in advanced breast
cancer specimens examined by Northern blot and im-
munohistochemical analysis. However, using a RT-PCR
assay, we unequivocally demonstrated the expression of
maspin in breast cancer in vivo, in both primary and
metastatic tumor specimens in advanced stages of the
disease, as well as in the MCF7 mammary carcinoma
cell line. Our result may be explained by the high sensi-
tivity of the technique used, although it is apparently in
conflict with the proposed function of maspin, since
high levels of maspin would be expected to act protec-
tively by blocking the enzymatic activity of a protease,
and thus be unlikely to be detectable in advanced
breast cancers specimens. However, the balance of
functions of proteases and their inhibitors in the con-
text of breast cancer is complex and high levels of
protease inhibitors may be of importance for reimplan-
tation of circulating tumor cells at distant loci. For
example, high levels of a proteolytic factor, the uro-
kinase-type plasminogen activator, and its inhibitor,
PAI-1, are both involved in breast cancer and have also
been claimed to be of independent prognostic value for
disease-free and overall survival [19]. Generation and
growth of metastases require the formation of a new
tumor stroma, which occurs via prevention of protease-
mediated degradation of the extracellular matrix, so
that the expression of a protease inhibitor like maspin
in metastatic breast cancer specimens in vivo is not
totally unexpected. On the other hand, on the basis of
the most recent studies of the primary structure of
maspin, it has been proposed that, unlike most serpins,
maspin is probably not an inhibitor but may be a
ligand-binding serpin, possibly related to thymosin p 4
[20], meaning that a role for this newly identified pro-
tein in breast cancer is still far from established. In any
case, since the aim of our study was to evaluate mRNA
maspin as a target for RT-PCR detection of a very
small number of mammary carcinoma cells, we chose
to assess the sensitivity of our assay in the MCF7 mam-
mary carcinoma cell line, previously found to be
maspin-negative on Northern blot analysis by Zou et al.
[16]. Thus, it is of particular importance that the ability
to detect 10 maspin-expressing mammary carcinoma
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cells mixed into one million normal PBMCs was close-
ly comparable, in the same cell line, to the sensitivity of
the RT-PCR assay for CK19 transcript, which is com-
monly expressed at high levels in epithelial tissues.
Given the paucity of information about the expres-
sion of this newly identified gene in human tissues and
the possible occurrence of an illegitimate transcription
phenomenon [21], we carefully ruled out the presence
of maspin transcripts by the same RT-PCR assay in a
series of 21 normal hemopoietic specimens collected
from healthy individuals. Thus, the specificity of our
assay, as a marker of circulating mammary carcinoma
cells, is definitely higher than that of the RT-PCR in
detection of K19 and MUC1 transcripts. In fact, the
results for CK19 are contradictory, with two studies
showing no transcription in normal blood samples [12,
22], and a third documenting illegitimate transcription
of this cytokeratine gene in about half of the controls
examined [14]. In our hands, the presence of CK19
transcripts was detectable in about the 30% of normal
PBMC samples examined by RT-PCR, suggesting that
the use of the CK19 marker is highly questionable and
that it ultimately prevents interpretation of the positive
findings in breast cancer patients. Furthermore, a study
of CK19 expression in lymph nodes found detectable
transcription in nodes from patients without cancer
using nested primers, although lowering the sensitivity
by using single-round PCR made it possible to distin-
guish malignant from normal specimens [23]. Similarly,
the RT-PCR assay for the MUC1 gene, initially pro-
posed to be a good marker for detecting breast cancer
micrometastases, has recently been found to generate a
high level of false-positive results in normal blood and
lymph nodes, when sensitivity is enhanced with sub-
sequently nested amplification and/or hybridization
[15]. Thus, it is possible that the RT-PCR assay for
maspin may also be flawed by the false-positive prob-
lem, if the sensitivity of the assay is increased. However,
it should be borne in mind that, as with most medical
testing, sensitivity and specificity need to be balanced.
This caveat will likely hold true for all attempts to
define micrometastases using the molecular detection
of tissue-specific gene transcripts, so that the value of
these methods, including the RT-PCR for maspin, will
be assessed only after their application in specific clini-
cal settings.
In order to test the feasibility of our assay in vivo, we
examined a series of patients with breast cancer at dif-
ferent stages to look for the presence of circulating
malignant cells in peripheral blood, and, whenever pos-
sible, in the bone marrow. The RT-PCR assay for
maspin was able to detect circulating breast carcinoma
cells in the peripheral blood of patients with stage IV
disease, and more frequently in those patients (3 of 9)
receiving systemic therapy at the time of the PBMC
sample collection. Similarly, Datta et al. showed the
presence of CK19-expressing cells by RT-PCR in only
4 of 19 patients with stage IV breast cancer receiving
chemotherapy, but they could not document malignant
cells in stages I, II or HI patients, nor in stage IV
patients not receiving systemic therapy near the time of
sample collection [12]. Using a highly sensitive im-
munocytochemical assay, Brugger et al. documented
concomitant tumor cell recruitment upon mobilization
of peripheral blood progenitor cells (PBPCs) with
multi-agent chemotherapy and a growth factor, in stage
IV breast cancer patients [25]. Lack of maspin PCR
positivity in the blood of the other stage IV patients
examined may have been due to consistently low num-
bers of circulating carcinoma cells below the threshold
of detection by the RT-PCR assay, to sequestration of
tumor cells at other sites and/or to intermittent
shedding of tumor cells in the circulation, possibly
leading to sampling errors. The RT-PCR assay is rapid,
with results available in 24 to 48 hours, and may be
combined with standard immunocytochemical meth-
ods to improve the detection of tumor cells. This assay
is potentially useful for evaluation of tumor cell conta-
mination of marrow as well as of stem-cell apheresis
harvests of stage IV patients following chemotherapy
plus a growth factor administration. However, only the
application of the maspin RT-PCR assay in a large
series of breast cancer patients with a long-term follow-
up will clarify whether this tool may ultimately be clini-
cally useful. Finally, we also obtained preliminary evi-
dence of maspin expression in epithelial tissues other
than mammary tissues, namely, liver and colon mucosa,
which could broaden the usefulness of this RT-PCR
method as a detection assay for a number of common
malignacies.
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